CONDUIT PHARMACEUTICALS INC. (Nasdaq:CDT)
Health Care/Life Sciences • Pharmaceuticals
CIK 1896212
Company
Conduit Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of clinical assets to address the unmet medical needs of patients, through exclusive relationships. Its medical needs in the areas of autoimmune disease and idiopathic male infertility. The company is headquartered in San Diego, CA.
Address
4995 Murphy Canyon Road
Suite 300
San Diego, California 92123
4995 Murphy Canyon Road
Suite 300
San Diego, California 92123
Employees
3
3
Stock Info
Close
$2.7700
$2.7700
Day Range
2.5100 - 2.7800
2.5100 - 2.7800
52 Week Range
0.9500 - 25.0000
0.9500 - 25.0000
Average volume
107.53K
107.53K
Short Interest
113.28K (02/15/24)
113.28K (02/15/24)
% of Float Shorted
1.10%
1.10%
Market Cap
$198.6M
$198.6M
Revenue
N/A
N/A
Net Income
$398.64K
$398.64K
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
|
Chief Executive Officer & Director David Joszef Tapolczay PhD |
|
Director James Bligh |
|
Director Andrew Regan PhD |
|
Non-Executive Chairman Freda C Lewis-Hall MD |
|
Independent Director Faith L Charles |
|
Independent Director Chele Chiavacci Farley |
|
Independent Director Jennifer Isacoff McNealey |
SEC filings
| Date | Form | Event |
|---|---|---|
| 4 Sep, 2024 | S-1 | |
| 19 Aug, 2024 | 424B3 | |
| 16 Aug, 2024 | 8-K | |
| 13 Aug, 2024 | 3 | |
| 13 Aug, 2024 | SC 13G/A | |
| 12 Aug, 2024 | 10-Q | |
| 8 Aug, 2024 | 8-K | |
| 7 Aug, 2024 | 8-K | |
| 11 Jul, 2024 | 8-K/A | |
| 1 Jul, 2024 | 8-K | |
| 11 Jun, 2024 | 4 | |
| 11 Jun, 2024 | 4 | |
| 31 May, 2024 | 8-K | |
| 16 May, 2024 | 424B3 | |
| 15 May, 2024 | 4 | |
| 15 May, 2024 | 4 | |
| 14 May, 2024 | 10-Q | |
| 2 May, 2024 | EFFECT | |
| 2 May, 2024 | POS AM | |
| 24 Apr, 2024 | 4 | |
| 24 Apr, 2024 | 4 | |
| 24 Apr, 2024 | 4 | |
| 16 Apr, 2024 | 8-K | |
| 16 Apr, 2024 | 10-K | |
| 1 Apr, 2024 | NT 10-K | |
| 12 Feb, 2024 | SC 13G/A | |
| 8 Feb, 2024 | SC 13G/A | |
| 2 Feb, 2024 | SC 13G/A | |
| 10 Jan, 2024 | S-8 | |
| 18 Dec, 2023 | 424B3 | |
| 15 Dec, 2023 | EFFECT | |
| 14 Dec, 2023 | 4 | |
| 13 Dec, 2023 | CORRESP | |
| 5 Dec, 2023 | 4 | |
| 5 Dec, 2023 | 4 | |
| 5 Dec, 2023 | 4 | |
| 5 Dec, 2023 | 4 | |
| 5 Dec, 2023 | 4 | |
| 5 Dec, 2023 | 4 | |
| 1 Dec, 2023 | S-1/A | |
| 1 Dec, 2023 | S-8 | |
| 1 Dec, 2023 | CORRESP | |
| 21 Nov, 2023 | 10-Q/A | |
| 20 Nov, 2023 | 10-Q | |
| 14 Nov, 2023 | NT 10-Q | |
| 30 Oct, 2023 | UPLOAD | |
| 17 Oct, 2023 | S-1 | |
| 5 Oct, 2023 | 8-K/A | |
| 2 Oct, 2023 | SC 13G | |
| 29 Sep, 2023 | SC 13D | |
| 29 Sep, 2023 | SC 13D/A | |
| 29 Sep, 2023 | SC 13G | |
| 29 Sep, 2023 | 8-K | CEO Change |
| 26 Sep, 2023 | 4 | |
| 26 Sep, 2023 | 4 | |
| 26 Sep, 2023 | 3 | |
| 26 Sep, 2023 | 3 | |
| 26 Sep, 2023 | 3 | |
| 26 Sep, 2023 | 3 | |
| 26 Sep, 2023 | 3 | |
| 26 Sep, 2023 | 3 | |
| 22 Sep, 2023 | CERT | |
| 22 Sep, 2023 | 25-NSE | |
| 22 Sep, 2023 | 8-A12B | |
| 21 Sep, 2023 | 8-K | |
| 13 Sep, 2023 | 424B3 | |
| 13 Sep, 2023 | 8-K | |
| 13 Sep, 2023 | 425 | |
| 7 Sep, 2023 | 8-K | |
| 7 Sep, 2023 | 425 | |
| 31 Aug, 2023 | 8-K | |
| 31 Aug, 2023 | 425 | |
| 23 Aug, 2023 | 424B3 | |
| 23 Aug, 2023 | 8-K | |
| 23 Aug, 2023 | 425 | |
| 16 Aug, 2023 | 425 | |
| 16 Aug, 2023 | 8-K | |
| 14 Aug, 2023 | 10-Q | |
| 11 Aug, 2023 | 424B3 | |
| 11 Aug, 2023 | EFFECT | |
| 11 Aug, 2023 | SEC STAFF | |
| 10 Aug, 2023 | CORRESP | |
| 8 Aug, 2023 | CORRESP | |
| 8 Aug, 2023 | S-4/A | |
| 7 Aug, 2023 | UPLOAD | |
| 28 Jul, 2023 | CORRESP | |
| 28 Jul, 2023 | S-4/A | |
| 21 Jul, 2023 | 8-K | |
| 21 Jul, 2023 | 425 | |
| 20 Jul, 2023 | UPLOAD | |
| 11 Jul, 2023 | S-4/A | |
| 11 Jul, 2023 | CORRESP | |
| 31 May, 2023 | UPLOAD | |
| 30 May, 2023 | SEC STAFF | |
| 15 May, 2023 | 10-Q | |
| 12 May, 2023 | CORRESP | |
| 12 May, 2023 | S-4 | |
| 11 May, 2023 | 425 | |
| 11 May, 2023 | 8-K | |
| 14 Apr, 2023 | 8-K | |
| 28 Mar, 2023 | 10-K | |
| 8 Mar, 2023 | 8-K | |
| 1 Mar, 2023 | UPLOAD | |
| 16 Feb, 2023 | SC 13D | |
| 14 Feb, 2023 | SC 13G/A | |
| 10 Feb, 2023 | SC 13G | |
| 10 Feb, 2023 | SC 13G | |
| 8 Feb, 2023 | 3 | |
| 8 Feb, 2023 | SC 13G/A | |
| 3 Feb, 2023 | 8-K | |
| 1 Feb, 2023 | DRS | |
| 1 Feb, 2023 | 8-K | |
| 30 Jan, 2023 | SC 13D/A | |
| 30 Jan, 2023 | 425 | |
| 30 Jan, 2023 | 8-K | |
| 3 Jan, 2023 | DEF 14A | |
| 23 Dec, 2022 | PRE 14A | |
| 25 Nov, 2022 | UPLOAD | |
| 23 Nov, 2022 | CORRESP | |
| 21 Nov, 2022 | UPLOAD | |
| 14 Nov, 2022 | 425 | |
| 14 Nov, 2022 | 8-K | |
| 8 Nov, 2022 | 425 | |
| 8 Nov, 2022 | 8-K | |
| 7 Nov, 2022 | 10-Q | |
| 11 Aug, 2022 | 10-Q | |
| 18 May, 2022 | 10-Q | |
| 16 May, 2022 | NT 10-Q | |
| 29 Mar, 2022 | 10-K | |
| 28 Mar, 2022 | 8-K | |
| 14 Feb, 2022 | SC 13D | |
| 14 Feb, 2022 | 8-K | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | SC 13G | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | 3 | |
| 11 Feb, 2022 | 3 | |
| 10 Feb, 2022 | SC 13G | |
| 8 Feb, 2022 | 8-K | |
| 4 Feb, 2022 | SC 13G | |
| 4 Feb, 2022 | 424B5 | |
| 2 Feb, 2022 | EFFECT | |
| 1 Feb, 2022 | CORRESP | |
| 1 Feb, 2022 | CORRESP | |
| 28 Jan, 2022 | S-1/A | |
| 26 Jan, 2022 | CORRESP | |
| 26 Jan, 2022 | RW WD | |
| 26 Jan, 2022 | RW | |
| 25 Jan, 2022 | CERT | |
| 24 Jan, 2022 | 8-A12B | |
| 21 Jan, 2022 | CORRESP | |
| 21 Jan, 2022 | CORRESP | |
| 6 Jan, 2022 | S-1 | |
| 20 Dec, 2021 | UPLOAD | |
| 9 Dec, 2021 | DRS |
Last update:2024-03-06 12:16:22.498959
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.